Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Ryanair Holdings Q1 Earnings

  Ryanair Holdings (NASDAQ:RYAAY) reported its Q1 earnings results on Monday, July 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
byBenzinga Insights
July 25, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Ryanair Holdings (NASDAQ:RYAAY) reported its Q1 earnings results on Monday, July 25, 2022 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Ryanair Holdings beat estimated earnings by 66.04%, reporting an EPS of $0.88 versus an estimate of $0.53.

Revenue was up $2.33 billion from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.54 which was followed by a 4.44% increase in the share price the next day.

 

To track all earnings releases for Ryanair Holdings visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Scilex Announces Filing Of A New Drug Submission To Health Canada’s Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For The Approval Of ELYXYB For Acute Treatment Of Migraine With Or Without Aura In Canada

By Happy Mohamed
December 26, 12:01 PM
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is

SCLX